Clearly, exploring the resistance mechanism and searching for new therapeutic targets to delay and reverse EGFR-TKIs resistance in lung adenocarcinoma is an urgent problem to be solved in tumor-targeted therapy and it is also essential for the treatment of NSCLC. This evidence concerns the gene EGFR and lung adenocarcinoma.